--- title: "MapLight reports $351.3 million in cash and investments" url: "https://aibio.space/news/maplight-reports-351-3-million-cash-investments-sees-funding-through/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-08-13" section: "Financings" tickers: "NASDAQ:MPLT" source: "https://www.sec.gov/Archives/edgar/data/1770069/000119312526349554/mplt-20260630.htm" summary: "MapLight reported $351.3 million in cash and investments at June 30, 2026 and cited funding through 2028. It also agreed to a private placement of about $1" --- By the aibio.space news desk. Sources - [MPLT 10-Q](https://www.sec.gov/Archives/edgar/data/1770069/000119312526349554/mplt-20260630.htm) - [MPLT 10-Q](https://www.sec.gov/Archives/edgar/data/1770069/000119312526224129/mplt-20260331.htm) [MPLT](https://aibio.space/companies/maplight-therapeutics/) 2026-08-13 # MapLight reports $351.3 million in cash and investments, sees funding through 2028 Tickers [MPLT](https://aibio.space/companies/maplight-therapeutics/) MapLight reported $351.3 million in cash and investments at June 30, 2026 and cited funding through 2028. It also agreed to a private placement of about $150.0 million at $11.38 a share. Six-month operating cash use was $96.0 million. ## Key facts - **Company**: MapLight Therapeutics, Inc. (NASDAQ: MPLT) - **News type**: Financings - **Primary source**: [MPLT 10-Q](https://www.sec.gov/Archives/edgar/data/1770069/000119312526349554/mplt-20260630.htm) *A distant skyline over open water. Photo: Matt Bango, CC0, via StockSnap. The picture shows the field, not the companies named.* MapLight Therapeutics (Nasdaq: [MPLT](https://aibio.space/companies/maplight-therapeutics/)) said in its [quarterly report for the period ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/1770069/000119312526349554/mplt-20260630.htm) that it held cash, cash equivalents and investments of $351.3 million, against an accumulated deficit of $481.4 million. The management discussion says the company's resources "will be sufficient to fund our operations through 2028." It adds that the estimate rests on assumptions that "may prove to be wrong" and that it could use its capital sooner than it expects. A private placement was signed the same day the report was filed. ## What the balance sheet shows The $351.3 million is made up of cash and cash equivalents of $71.6 million, short-term investments of $233.1 million and long-term investments of $46,616 thousand. Total liabilities were $20,049 thousand, so the company carries almost no debt. The company has never earned revenue from any source and says it does not expect product sales in the foreseeable future. Spending is rising fast. Net cash used in operating activities was $96.0 million for the six months, up from $59.5 million a year earlier. The six-month net loss was $120.9 million, compared with $52.2 million. For the second quarter alone, research and development expense was $53,435 thousand, against $26,846 thousand a year before, and general and administrative expense was $10,113 thousand, against $3,817 thousand. The net loss for the quarter was $60,192 thousand. Stock-based compensation, a non-cash charge, was $18,262 thousand for the six months, against $360 thousand a year earlier. The balance sheet shrank. Total assets fell to $368,348 thousand from $479,512 thousand at the end of 2025. Stockholders' equity was $348,299 thousand, down from $458,372 thousand. ## The August private placement On August 13, 2026 MapLight agreed to sell 9,197,887 shares of common stock to institutional investors at $11.38 a share. Some purchasers took pre-funded warrants for 3,983,168 shares instead, at the same price less $0.0001 per share, with an exercise price of $0.0001. The company expects gross proceeds of approximately $150.0 million before placement agent fees and offering expenses. The 10-Q does not name the placement agent, the purchasers or counsel. The $11.38 price compares with the $17.00 a share at which the company sold stock in its October 2025 initial public offering. That offering raised gross proceeds of $288.4 million and net proceeds of $261.6 million from 16,962,500 shares, and a concurrent private placement of 476,707 shares at $17.00 brought in net proceeds of $7.5 million. MapLight also signed a registration rights agreement. It must file a resale registration statement within 30 days of closing, or owe liquidated damages of 1.0% of the amount each purchaser paid for each 30-day period, subject to caps. The share count was 45,436,867 at June 30, 2026. The cover of the report lists 43,650,321 voting shares and 2,727,511 non-voting shares outstanding at the report date, before any placement shares or warrant shares. ## Going concern and obligations The liquidity note is headed "Liquidity and Going Concern." It says the company has had negative operating cash flows since inception, expects operating losses for the foreseeable future and depends on raising more capital. It says the $351.3 million is enough for at least twelve months from the date the statements were issued. The notes to the financial statements commit only to twelve months, a narrower statement than the through-2028 line in the management discussion. The company's operating plans include funding multiple clinical trials of its lead candidate, ML-007C-MA. It also names ML-004 as a candidate. The filing calls its approach to discovering and developing candidates unproven and says it has not yet shown it can win regulatory approval. Under an asset purchase agreement with NeuroSolis, Inc., MapLight may issue up to 62,083 shares on milestones. It issued 26,607 in June 2025 and says it is uncertain whether the remaining 35,476 shares will be required. Grants from the Michael J. Fox Foundation totaling $25.7 million were fully received, but the company may owe repayments of up to two times the grants, tied to net product sales. MapLight reports no material legal proceedings. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story MPLT MapLight Therapeutics, Inc. NASDAQ ยท United States Open the starter desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/maplight-reports-351-3-million-cash-investments-sees-funding-through/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "MapLight reports $351.3 million in cash and investments", 2026-08-13, https://aibio.space/news/maplight-reports-351-3-million-cash-investments-sees-funding-through/